Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

The Lancet

Volumn 374, Issue 9694, 2009, Pages 989-997

  O'Donoghue, Michelle L ^a   Braunwald, Eugene ^a   Antman, Elliott M ^a   Murphy, Sabina A ^a   Bates, Eric R ^b   Rozenman, Yoseph ^c   Michelson, Alan D ^d   Hautvast, Raymond W ^e   Ver Lee, Peter N ^f   Close, Sandra L ^g   Shen, Lei ^g   Mega, Jessica L ^a   Sabatine, Marc S ^a   Wiviott, Stephen D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e Location Alkmaar   (Netherlands)

^f Northeast Cardiology Associates   (United States)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; RABEPRAZOLE; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GENETIC ASSOCIATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 70249139788     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61525-7     Document Type: Article

References (28)

1. Jernberg T., Payne C.D., Winters K.J., et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27 (2006) 1166-1173
2. Brandt J.T., Payne C.D., Wiviott S.D., et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153 (2007) 66.e9-66.e16
3. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932
4. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118 (2008) 1894-1909
5. Gilard M., Arnaud B., Le Gal G., Abgrall J.F., and Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 4 (2006) 2508-2509
6. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008) 256-260
7. Sibbing D., Morath T., Stegherr J., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101 (2009) 714-719
8. Juurlink D.N., Gomes T., Ko D.T., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180 (2009) 713-718
9. Ho P.M., Maddox T.M., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 (2009) 937-944
10. Stanek EJ, Aubert RE, Flockhart DA, et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcomes Study. Paper presented at: SCAI 32nd Annual Scientific Sessions. Las Vegas, NV, 2009.
11. Dunn S.P., Macaulay T.E., Brennan D.M., et al. Baseline proton pump inhibitor use is assocated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 118 (2008) 815A (abstract).
12. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
13. Wiviott S.D., Antman E.M., Gibson C.M., et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 152 (2006) 627-635
14. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362
15. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton-pump inhibitors. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf (accessed July 23, 2009).
16. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). http://www.fda.gov/cder/drug/early_comm/clopidogrel_bisulfate.htm (accessed July 23, 2009).
17. Li X.Q., Andersson T.B., Ahlstrom M., and Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32 (2004) 821-827
18. Sibbing D., Stegherr J., Latz W., et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30 (2009) 916-922
19. Collet J.P., Hulot J.S., Pena A., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373 (2009) 309-317
20. Giusti B., Gori A.M., Marcucci R., et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 103 (2009) 806-811
21. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360 (2009) 363-375
22. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119 (2009) 2553-2560
23. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
24. Saw J., Steinhubl S.R., Berger P.B., et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108 (2003) 921-924
25. Wienbergen H., Gitt A.K., Schiele R., et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 92 (2003) 285-288
26. Gorchakova O., von Beckerath N., Gawaz M., et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 25 (2004) 1898-1902
27. Eli Lilly and Co. Efficient labeling information. http://pi.lilly.com/us/effient.pdf (accessed July 23, 2009).
28. Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G., and Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157 (2009) 148.e141-148.e145